RxDoctor Payments DataLook up a doctor →

John Doane, MD

Ophthalmology · Leawood, KSNPI 1851384119

Payments from drug & device makers

$960,170in general payments, 2019–2025

Across 259 payments — averaging $3707.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$627K
  • Rxsight Inc$288K
  • Carl Zeiss Meditec USA, Inc.$36K
  • Alcon$8K
  • Carl Zeiss Meditec AG$445
  • Novartis$380
  • plus $235 from 7 others
$92,923in research payments, 2019–2025

Across 57 payments — averaging $1630.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rxsight Inc$72K
  • Carl Zeiss Meditec, Inc.$21K

What the payments were for

  • Consulting fees$351,22371%
  • Speaking & faculty fees$126,42625%
  • Travel & lodging$5,8731%
  • Food & beverage$7,3521%
  • Education$4,9081%
  • Gifts$4300%
  • Entertainment$490%
  • Other$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960,170 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$423,173
Medicare patients
639
Services billed
2,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,154$47,509
Ciprofloxacin Hcl822$8,687
XiidraLifitegrast12$8,183
Latanoprost71$586
Ketorolac Tromethamine15$583
Acyclovir32$330
Timolol Maleate29$239
Ofloxacin14$170
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim19$147
Amoxicillin15$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$91$8,18312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Leawood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →